TrialInternational journal of hematology2015

A phase II study of bendamustine plus rituximab in Japanese patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma previously treated with rituximab: BRB study.

Kimihiro Matsumoto et al.PubMed ↗Publisher ↗

No numbers read from the abstract.